Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MYHDfZRwfG:6aXOgRZN{[Xl? NVnVRWt[OTBibl2= MoC0O|IhcA>? MlrnSG1UVw>? MV;Qc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= MU[yOFkxODh5Mx?=
HT-29 MUTDfZRwfG:6aXOgRZN{[Xl? M2\B[VExKG6P NXnpSVhKPzJiaB?= NHzTT3NFVVOR M{noTnBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MViyOFkxODh5Mx?=
HT-29 NGDzSmZEgXSxdH;4bYMhSXO|YYm= MYSxNEBvVQ>? MkG4O|IhcA>? NFr6UGFFVVOR M3PLZ3BwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 MnK1NlQ6ODB6N{O=
PC3 MVHLbY5ie2ViQYPzZZk> M4H6SVExOCCwTR?= MXSxJIg> MnfJSG1UVw>? NEfNNJZRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> NIraO5AzOTl5OE[4Ny=>
PC3 NX\UeGZJU2mwYYPlJGF{e2G7 MlnCNVAxKG6P MV[xJIg> MXzEUXNQ NUjkPVhUTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MUeyNVk4QDZ6Mx?=
PC3 NIXXN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6xMlUh|ryP NUK1NWNiOSCq MVPEUXNQ NHfPbmpKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= M3W3d|IyQTd6Nkiz
HEK293 MYTGeY5kfGmxbjDBd5NigQ>? M{WxWVExOCCwTR?= MnTuPEBp NIj3WFJFVVOR NHH2TGVKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NFTrTJMzOTV|OUOwNS=>
BT-20 NITxUHJMcW6jc3WgRZN{[Xl? Ml;1NlAh|ryP NVfBTpJvTE2VTx?= M3LEN2Rw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w NVXnZYpjOjF|NUO1OVE>
U937 M17U[2FvfGmkYXP0[ZJq[WxiQYPzZZk> NGjuPXI2OCEQvF2= M3;EVlQ5KGh? MljQSG1UVw>? M2HXOGlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= MViyNVE1OjFyNh?=
U937 MorDRY51cWKjY4TldolidCCDc4PhfS=> M4jKTlUxKM7:TR?= MkXXOFghcA>? MonjSG1UVw>? NFq4S2lFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| MX6yNVE1OjFyNh?=
U937 M4fhbGFvfGmkYXP0[ZJq[WxiQYPzZZk> NUCwU3hZPTBizszN MXS0PEBp MnKzSG1UVw>? MVXEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> NEHvT4MzOTF2MkGwOi=>
MCF-7 NGDQVopCfXSxcHjh[5khSXO|YYm= NE[0NFU{OCCwTR?= NXvOOoZMPCCq MYjEUXNQ NVHCUlhxUW6mdXPld{BifXSxcHjh[5k> NVSyOJo{OjByMkixN|Q>
U87MG NH;zUpdMcW6jc3WgRZN{[Xl? M1XrXFEh|ryP M3H1dlYhcA>? MXXEUXNQ M4fiW3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w NUSwcJFWOTl6NEi0NFQ>
U87MG MlPnT4lv[XOnIFHzd4F6 M{XvUFEh|ryP MX:2JIg> MnS0SG1UVw>? MUDQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= MXixPVg1QDRyNB?=
U87MG M{PEXWtqdmG|ZTDBd5NigQ>? MnKwNUDPxE1? MX[2JIg> M{[1b2ROW09? NUf4R3RxTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MUKxPVg1QDRyNB?=
U87MG NHzjUXZMcW6jc3WgRZN{[Xl? M1e2ZVEh|ryP MmDMOkBp NY\O[3o3TE2VTx?= MmLuSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v MnHBNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb MnvwRZV1d3CqYXf5JGF{e2G7 MV:wMlIh|ryP NFWydlczPCCq NH7GdG1FVVOR M2jVVGlv\HWlZYOgZZV1d3CqYXf5 NF\DcW4yQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 M1y5UWF2fG:yaHHnfUBCe3OjeR?= MUCwMlIh|ryP MUOyOEBp M3fV[mROW09? MUjJcoR2[2W|IHH1eI9xcGGpeR?= M3;B[VE5OzlzOUS5
H4 M2XBZmZ2dmO2aX;uJGF{e2G7 MkLVNE4zKM7:TR?= NWWwPW83OjRiaB?= M4LsfGROW09? NHWxWWlKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ NGrIb4kyQDB{NEW4OC=>
HeLa NVjXPYQyTnWwY4Tpc44hSXO|YYm= MmTtNVAxKG6P MkHZN|YhcA>? NIKyeHNFVVOR NGTkbopKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MXWxO|U3OzN6NR?=
HeLa MVzGeY5kfGmxbjDBd5NigQ>? MoLvNVAxKG6P MXOzOkBp NUPBbVBpTE2VTx?= NG\mOIlKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? MV:xO|U3OzN6NR?=
HeLa NF7Q[4pHfW6ldHnvckBCe3OjeR?= MoC4NVAxKG6P MlOyN|YhcA>? M1H5VWROW09? MYfJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NFzBdmUyPzV4M{O4OS=>
SYF M3zodWZ2dmO2aX;uJGF{e2G7 NVPjNIlsOTByIH7N M33HOVI1KGh? MWDEUXNQ MX7JcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NYXacXJ5OTd3NkOzPFU>
SYF MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfnNVAxKG6P M1vTUlI1KGh? M2r2eWROW09? M4frUWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= NVzB[2tlOTd3NkOzPFU>
HEK293T NGfiOYlCdnSrdnnyZYwhSXO|YYm= NXrWWnAzOSCwTR?= NYLqem1jPCCm NFLjVmJFVVOR NXy1[osyUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> MlHKNVc1QDV3MEG=
HEK293T Ml73RY51cX[rcnHsJGF{e2G7 NYWzUoxCOSCwTR?= MmexOEBl NH;l[3pFVVOR MmPOTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= MV6xO|Q5PTVyMR?=
PBMC NIDV[pVHfW6ldHnvckBCe3OjeR?= NUXUVm9rOSCwTR?= M3XRcFE1KGR? NYrJb4p7TE2VTx?= NGLlbW1T\WS3Y3XzJGNEWjViZHXud4l1gQ>? NF\zTGYyPzR6NUWwNS=>
PBMC MkfrSpVv[3Srb36gRZN{[Xl? NFPC[YwyKG6P MV6xOEBl M3\jUGROW09? M3;Kc2Rw\XNibn;0JIFn\mWldDDDXGNTPCCmZX7zbZR6 MoqyNVc1QDV3MEG=
HEK293 cells MU\LbY5ie2ViQYPzZZk> MUK1NEBvVQ>? NI[wZYU1PSCvaX6= NHzYOWdFVVOR NF7HTJFKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P NGDGbWIyPzN3MEm1Ny=>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MVLGeY5kfGmxbjDBd5NigQ>? MYOxNFAhdk1? NIXKXWE1KGh? NFzMfGpFVVOR MYDJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> NIrvV4wyPzF{OEK2Ni=>
Human mixed lymphocyte M3:yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL2OUBvVQ>? MkLOSG1UVw>? Mn7RTWM2OD1zLk[gcm0v MkHaNVYyQDV6NkW=
Lewis rat lymph node cells MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTSelNzPSEQvF2= MlTMSG1UVw>? MkTETWM2OD1{Lk[g{txO M4D2V|E3OTh3OE[1
cells from the thymus of normal BALB/c mice M2OxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m5WVExKG6P M1jwU|czKGh? M3\IcWROW09? MYXJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P NYe3eGREOTByMkG5OFg>
MRK-nu-1 NVnofI96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K4OWlEPTB;MD64OFUheE1? Mlz2V2FPT0WU
OCUB-M Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq4VJRKSzVyPUWuNlQheE1? NFfkWWZUSU6JRWK=
SF539 NGrhN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFzLk[gdG0> NEHOcVFUSU6JRWK=
ES4 NVHZWJNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJzLkWgdG0> NYDx[mdGW0GQR1XS
RL95-2 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOxNZRnUUN3ME2xNFcheE1? M{TTOXNCVkeHUh?=
LC-2-ad NWPxXo12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrlTWM2OD12MkOgdG0> MYHTRW5ITVJ?
Daudi MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X6e2lEPTB;NEO0JJBO NH64[4pUSU6JRWK=
NTERA-S-cl-D1 Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjoVlhKSzVyPUS0N{BxVQ>? MWrTRW5ITVJ?
OS-RC-2 M1T5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCbWVMUUN3ME22OVIheE1? MljkV2FPT0WU
VA-ES-BJ NWHIWYF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nweWlEPTB;N{KzJJBO NVflfFhlW0GQR1XS
GR-ST NFj4UHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7xTWM2OD16NE[gdG0> MXrTRW5ITVJ?
SW872 NFXyOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTGTWM2OD16NE[gdG0> NYfqRWV{W0GQR1XS
NOS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\GTWM2OD16N{GgdG0> NYjOOWp1W0GQR1XS
MC116 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK0TWM2OD17OEWgdG0> MlnjV2FPT0WU
NCI-H1355 NEDCXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDSXJZKSzVyPUGuNFEhdk1? MV;TRW5ITVJ?
RPMI-8226 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3GdIhHUUN3ME2xMlE6KG6P NXnHdHZrW0GQR1XS
TE-15 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm0TWM2OD1zLkO2JI5O NUHpbWtnW0GQR1XS
Ramos-2G6-4C10 NFPodoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjSRmxKSzVyPUGuOFYhdk1? MWrTRW5ITVJ?
KU812 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwMEGgcm0> MX3TRW5ITVJ?
EW-1 M{nkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHITWM2OD1{LkG3JI5O MWHTRW5ITVJ?
KS-1 NWDEUXRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJwNEWgcm0> M4TIe3NCVkeHUh?=
SK-LMS-1 NYjDRWdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD5bmFXUUN3ME2yMlQ6KG6P NX;YeGxPW0GQR1XS
TGBC1TKB NF3vcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELTN3hKSzVyPUKuOlkhdk1? NGjNUZVUSU6JRWK=
TE-6 NYDuZ4gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDXNFlKSzVyPUKuO|chdk1? MmTtV2FPT0WU
ETK-1 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJwOEKgcm0> NVv4d|NtW0GQR1XS
BE-13 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn6TWVKSzVyPUKuPVkhdk1? MVrTRW5ITVJ?
A3-KAW MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzLXppQUUN3ME2yMlk6KG6P NUjYelZRW0GQR1XS
TE-10 NGnpdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KwVmlEPTB;Mz6zJI5O NH7iZ5RUSU6JRWK=
DOHH-2 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXhTWM2OD1|LkO1JI5O NUnoTo8yW0GQR1XS
ES6 NYjBd5k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITtPI9KSzVyPUOuOFMhdk1? NFHEWVFUSU6JRWK=
OPM-2 NFzJfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HjPWlEPTB;ND6xOUBvVQ>? NHHJTmRUSU6JRWK=
SH-4 M4W5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT2WJdKSzVyPUSuN|Qhdk1? NICz[HZUSU6JRWK=
NB13 M33Wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz0TWM2OD12LkO2JI5O MoDwV2FPT0WU
HUTU-80 NHe0R2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnoe5pmUUN3ME20MlQzKG6P MUjTRW5ITVJ?
CCRF-CEM MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnId5pKSzVyPUSuPVQhdk1? MnvqV2FPT0WU
TGBC24TKB NGXRfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXrTWM2OD13LkWxJI5O MUHTRW5ITVJ?
697 NXnnd4pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi4bHJXUUN3ME22MlI5KG6P NUjJ[lY{W0GQR1XS
J-RT3-T3-5 NWSxTZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXpTWM2OD14LkS2JI5O NID5PGNUSU6JRWK=
KALS-1 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPiTWM2OD14LkW2JI5O MWPTRW5ITVJ?
no-10 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHRd4c1UUN3ME23MlI6KG6P MXXTRW5ITVJ?
SK-NEP-1 NFTFeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\od2lEPTB;OD63PUBvVQ>? NX\IXXNzW0GQR1XS
L-540 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLNTWM2OD1zMD60NkBvVQ>? NVvF[mVWW0GQR1XS
JiyoyeP-2003 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HFT2lEPTB;MUCuPVQhdk1? NGHMdnFUSU6JRWK=
HH NUfnWnllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDsTWM2OD1zMT6zPUBvVQ>? NVzj[4c5W0GQR1XS
SR M{TMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLNWZJ7UUN3ME2xNU41PSCwTR?= NFrHcoFUSU6JRWK=
QIMR-WIL MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLYTWM2OD1zMT64OUBvVQ>? NHju[|VUSU6JRWK=
A4-Fuk Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITPUnJKSzVyPUGzMlEzKG6P NEiyXGtUSU6JRWK=
CESS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF|LkGzJI5O NXrBb20zW0GQR1XS
KE-37 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37FfGlEPTB;MU[uNFchdk1? NFLRd5NUSU6JRWK=
SK-UT-1 NVnVZWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jtXWlEPTB;MU[uPFEhdk1? NILNPHBUSU6JRWK=
SIG-M5 MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF5LkK1JI5O MVPTRW5ITVJ?
HT NUDQSZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[1TVVKSzVyPUG3MlYhdk1? Mn;ZV2FPT0WU
DEL NVq4dXg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH4Vo9KSzVyPUG3Mlk6KG6P M4ezc3NCVkeHUh?=
SK-PN-DW NV7sV5psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorFTWM2OD1{MD6yN{BvVQ>? M3vtSnNCVkeHUh?=
RPMI-8402 NHPTSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HiTGlEPTB;MkGuO|chdk1? MXPTRW5ITVJ?
RPMI-6666 NV3BXnduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ2LkSyJI5O MVLTRW5ITVJ?
NCI-H720 M2jiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTwTWM2OD1{NT60NUBvVQ>? MWLTRW5ITVJ?
EW-16 M4fnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ4Lki3JI5O M3XqRXNCVkeHUh?=
BL-70 NETufHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fCfWlEPTB;MkiuN|ghdk1? NXvBNWdQW0GQR1XS
SF126 NHL6WI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3NeWpIUUN3ME2zNE4{QCCwTR?= NFXNSXZUSU6JRWK=
BC-1 NGG4VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfqZYhOUUN3ME2zNU4zPiCwTR?= MoHCV2FPT0WU
MHH-PREB-1 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ZTWM2OD1|Mj60OEBvVQ>? NVy2SmVpW0GQR1XS
A101D M{TMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;nTWM2OD1|Mj62NkBvVQ>? MV7TRW5ITVJ?
NMC-G1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN|Lk[3JI5O M2fGSHNCVkeHUh?=
LB1047-RCC NETGbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r2UGlEPTB;M{SuOlkhdk1? NFH5[lJUSU6JRWK=
EM-2 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXsTJozUUN3ME2zPE42OyCwTR?= MYPTRW5ITVJ?
COLO-684 M{DkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN7Lkigcm0> NInYNoxUSU6JRWK=
Becker NWrOVWx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rt[GlEPTB;NEGuNFUhdk1? NWLzV3h3W0GQR1XS
BL-41 M1jNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLlTWM2OD12Mz62OkBvVQ>? MV;TRW5ITVJ?
MDA-MB-134-VI M{HBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTR2LkCyJI5O NH7mW29USU6JRWK=
L-363 M2rYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTR2LkezJI5O NIjtTpNUSU6JRWK=
ECC4 NVfy[5pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PvZmlEPTB;NESuO|ghdk1? M4DlVnNCVkeHUh?=
A388 MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml60TWM2OD12ND64NkBvVQ>? NXrrd|hiW0GQR1XS
HEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LQd2lEPTB;NEmuO|khdk1? NVH6RVR7W0GQR1XS
RKO NFP3R5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\pVmlEPTB;NUCuNlkhdk1? MVTTRW5ITVJ?
KINGS-1 NVP2SpVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHyVlU2UUN3ME21NU42PSCwTR?= NXHueHdmW0GQR1XS
EB-3 NGfyfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTV{Lk[3JI5O M{O4XHNCVkeHUh?=
ARH-77 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XuZmlEPTB;NUKuPEBvVQ>? M17xSHNCVkeHUh?=
GCIY NWrtSphJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELaWohKSzVyPUWzMlQ3KG6P NF7iXmdUSU6JRWK=
NCI-H1304 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK2TWM2OD13Nz6yNkBvVQ>? NF7TboJUSU6JRWK=
KARPAS-299 NFPXSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZzLkiyJI5O NFHqNo9USU6JRWK=
IA-LM NVnjeHR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTZ6LkGzJI5O NF;QSJRUSU6JRWK=
GI-1 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O4VmlEPTB;N{CuN|khdk1? MnXuV2FPT0WU
TE-11 NIqzU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fXV2lEPTB;N{euNVchdk1? MkjLV2FPT0WU
LS-411N M2TjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7yRlhWUUN3ME23O{42PyCwTR?= Mn:yV2FPT0WU
no-11 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG3UpViUUN3ME24N{4zPCCwTR?= M135WXNCVkeHUh?=
MV-4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nLTWlEPTB;OEOuO|Mhdk1? MVnTRW5ITVJ?
BV-173 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDxcXVKSzVyPUizMlk4KG6P NEK5SVhUSU6JRWK=
CMK MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq5TWM2OD16ND6xOkBvVQ>? M{iwTXNCVkeHUh?=
LC4-1 NYrNb2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DET2lEPTB;OE[uO|Ihdk1? NH7iTZBUSU6JRWK=
COR-L279 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTh5LkK1JI5O MojSV2FPT0WU
NCI-H209 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X1TWlEPTB;OEeuOFEhdk1? NGO3OGFUSU6JRWK=
Raji MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7wbFh3UUN3ME24PU44OiCwTR?= MUDTRW5ITVJ?
LB996-RCC NV;xcGZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfyPFNKSzVyPUmzMlQ{KG6P MoHoV2FPT0WU
NCI-H526 NW\UdGJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP6TWM2OD17Mz61PUBvVQ>? MlO3V2FPT0WU
KGN NHzj[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu3fGxkUUN3ME25Ok4zQSCwTR?= M37VS3NCVkeHUh?=
MOLT-4 NULQNpF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr2c5JKSzVyPUm2Mlc6KG6P M{jkeXNCVkeHUh?=
PF-382 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r6S2lEPTB;OU[uO|khdk1? MXPTRW5ITVJ?
BC-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTl7LkG4JI5O NUG1dFRnW0GQR1XS
KARPAS-422 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFyMj6wPUBvVQ>? M{ThXnNCVkeHUh?=
SBC-1 NGLKU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTWTWM2OD1zMEeuO|Uhdk1? NEjYZVlUSU6JRWK=
LC-1F M2HodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rkZWlEPTB;MUC4MlA2KG6P NWG0R3h2W0GQR1XS
GB-1 NUmwbmJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7yTWM2OD1zMEmuNFIhdk1? MoDmV2FPT0WU
SNB75 M{Dpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\DWoxKSzVyPUGxPU43QSCwTR?= NXTjZ4xKW0GQR1XS
BB65-RCC M4nEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHZTWM2OD1zMUmuPVMhdk1? M3n1RXNCVkeHUh?=
NCI-N87 M1TaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHPNWl3UUN3ME2xNlEvQThibl2= MX3TRW5ITVJ?
IST-MEL1 M2rIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF{Mj6zPEBvVQ>? MoPkV2FPT0WU
HOP-62 M{jSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF{Nj64PUBvVQ>? NWK5V5N[W0GQR1XS
ACN M2\5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm2WFRKSzVyPUG0Ok44PSCwTR?= NYf6S2k{W0GQR1XS
DMS-114 NVqxSZY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTmTWM2OD1zNUCuOlchdk1? NYf1cmpEW0GQR1XS
MLMA NHT0SVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKzdZJxUUN3ME2xOVkvQDhibl2= NEDHdXNUSU6JRWK=
HT-144 M{DiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjWdnNbUUN3ME2xOlUvPDNibl2= MYnTRW5ITVJ?
C2BBe1 M2rtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF4Nz63OkBvVQ>? M1TlPXNCVkeHUh?=
L-428 M3PBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXWTWM2OD1zN{euO{BvVQ>? MVjTRW5ITVJ?
DU-4475 M2DkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjoOXBKSzVyPUG4O{43QCCwTR?= NHrvbWZUSU6JRWK=
CP67-MEL NVKzUHZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF7OT6zPEBvVQ>? MoPOV2FPT0WU
MEG-01 NEnhO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXBfFBKSzVyPUKwNU46PiCwTR?= M1vSfnNCVkeHUh?=
IST-SL2 NUmxPI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPSVZFwUUN3ME2yNFgvPjNibl2= NHXlT5NUSU6JRWK=
ES8 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XXcmlEPTB;MkK1Mlk1KG6P NIjmSnZUSU6JRWK=
COLO-800 NVLaS5hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn1TWM2OD1{M{WuNlghdk1? MULTRW5ITVJ?
MFH-ino NHzne|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzqb3lVUUN3ME2yN|UvQDRibl2= NXPacXg1W0GQR1XS
OVCAR-4 NHrmd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ|Nz6yOEBvVQ>? MVPTRW5ITVJ?
PSN1 M3uyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT3TWM2OD1{NEKuO|Ehdk1? M4[5cnNCVkeHUh?=
EW-12 NEWwflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHsTWM2OD1{NEOuNUBvVQ>? MV7TRW5ITVJ?
HCC1599 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ4MT60O{BvVQ>? MULTRW5ITVJ?
SJSA-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm3dXZOUUN3ME2yO|EvPDZibl2= MkHkV2FPT0WU
ST486 NV;oNJpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\OTWM2OD1{OU[uNVQhdk1? NEHxbHBUSU6JRWK=
NOMO-1 NUHXNW9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXHc|VKSzVyPUOwNE4zOSCwTR?= M36xVnNCVkeHUh?=
MN-60 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX2SFFKSzVyPUOwOU4{OiCwTR?= MW\TRW5ITVJ?
HCC1187 NHnMW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK2Tm5KSzVyPUOwO{4zPSCwTR?= MkXnV2FPT0WU
SW982 NU\1[GtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPYUlRKSzVyPUOxOE44PSCwTR?= MXvTRW5ITVJ?
LB647-SCLC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH4[4NKSzVyPUOyPE44OSCwTR?= M{\ER3NCVkeHUh?=
HC-1 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLK[o9SUUN3ME2zN|UvPSCwTR?= NIjIdXBUSU6JRWK=
EHEB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYezOHhqUUN3ME2zN|cvPTJibl2= MkC1V2FPT0WU
TUR NHH0TWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PEeGlEPTB;M{[zMlk2KG6P M2n0R3NCVkeHUh?=
LU-139 NVm2SY14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f2fGlEPTB;M{e4MlAzKG6P NIDaWYFUSU6JRWK=
NB1 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vDR2lEPTB;M{i0MlQ2KG6P NGDqT3RUSU6JRWK=
BB30-HNC NHLkT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7nTHRKSzVyPUO4PE4{OiCwTR?= MnzpV2FPT0WU
HAL-01 NUP5VpJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXJTWM2OD1|OEmuNlYhdk1? NHq3c2NUSU6JRWK=
K5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[5fYlKSzVyPUSxNU4{PyCwTR?= M3HoW3NCVkeHUh?=
MZ2-MEL M{DteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHTXlZFUUN3ME20NVMvPjRibl2= MnPyV2FPT0WU
RXF393 NF3aN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTzZoZCUUN3ME20NVYvPDVibl2= MmPPV2FPT0WU
NCI-H1648 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTRzNz61N{BvVQ>? Mln4V2FPT0WU
TE-12 M2SybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HCemlEPTB;NEO0MlI3KG6P M1jsOnNCVkeHUh?=
EoL-1- MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHriXZlKSzVyPUSzO{46QCCwTR?= MX7TRW5ITVJ?
JAR NWL0S5Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonKTWM2OD12M{iuOlIhdk1? NXfhdZg5W0GQR1XS
DSH1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLUTWM2OD12NUiuPVEhdk1? M1PDXXNCVkeHUh?=
NCI-H187 NHTteY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHtOJZKSzVyPUS2Nk45OSCwTR?= M1W5OHNCVkeHUh?=
HCE-4 NITGeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGzfHBiUUN3ME20O|cvPjZibl2= NF2xOpJUSU6JRWK=
8-MG-BA NULWTmJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTV6MT61NkBvVQ>? NX;PVJlnW0GQR1XS
KLE NGLQfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnyXFRvUUN3ME21PFUvOiCwTR?= M{DaTXNCVkeHUh?=
KNS-42 M1qzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXYXHJPUUN3ME21PFYvQDFibl2= NUPxcmVbW0GQR1XS
MSTO-211H NXX0T3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHYTWM2OD14MEmuO|Qhdk1? MVTTRW5ITVJ?
GDM-1 M3jLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi5TWM2OD14MUSuNFkhdk1? NEjKfVNUSU6JRWK=
TE-1 NVj6TnNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHoNnlqUUN3ME22OFYvOTJibl2= MX3TRW5ITVJ?
BT-474 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTZ2Nz6wOkBvVQ>? MWfTRW5ITVJ?
KARPAS-45 NU\vOJJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2SzUGlEPTB;NkS3MlYhdk1? NHjmeGtUSU6JRWK=
MOLT-16 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PNRmlEPTB;NkS3Mlk{KG6P M4fMPHNCVkeHUh?=
KURAMOCHI MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPPTHJKSzVyPU[1O{42OSCwTR?= NUPhbFlxW0GQR1XS
K-562 NVrLdplwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXXUpVKSzVyPU[2PU42OSCwTR?= NVrpcYFEW0GQR1XS
EKVX MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjMVYIzUUN3ME22O|IvPzFibl2= MX\TRW5ITVJ?
GAK NGjC[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnyxTWM2OD14N{WuN{BvVQ>? NWjISmloW0GQR1XS
NCI-SNU-5 NHztXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHNdmZKSzVyPU[5NE4xOSCwTR?= NXrTNJluW0GQR1XS
NCI-H2126 NIjTb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTd{Nj64O{BvVQ>? NIO1ZZhUSU6JRWK=
CTV-1 NUDrWYlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vkTGlEPTB;N{S0Mlkhdk1? MlrqV2FPT0WU
SW962 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTd2OD60OEBvVQ>? MoPIV2FPT0WU
MONO-MAC-6 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTd3Nj65N{BvVQ>? M1XSfHNCVkeHUh?=
NCI-H748 NW\wZpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUexXVN7UUN3ME23OVgvQTlibl2= NIP6U4lUSU6JRWK=
NCI-H524 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rwe2lEPTB;N{iwMlc{KG6P MUTTRW5ITVJ?
LS-123 NWq2SpQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f2cWlEPTB;N{m1MlY6KG6P M3vhVHNCVkeHUh?=
NB7 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PxemlEPTB;OEG0MlE1KG6P NEPHO4xUSU6JRWK=
LS-1034 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\5Zo9YUUN3ME24NlgvQThibl2= NXLneItNW0GQR1XS
TE-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPDTWM2OD16OEOuOVYhdk1? NWG4XWpFW0GQR1XS
A704 Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTh7OT6xOUBvVQ>? MUHTRW5ITVJ?
TK10 NHH4VYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO0fXNUUUN3ME25NVYvODNibl2= NHPOclVUSU6JRWK=
NCI-H345 NWDRcmg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHKSnM5UUN3ME25OFMvOjJibl2= NXfTNlNNW0GQR1XS
CGTH-W-1 NF3IXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW4SmlKSzVyPUm0PE4yOyCwTR?= M3rLS3NCVkeHUh?=
NCI-H510A MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrQcGtKSzVyPUm4OU4yOiCwTR?= M2\lU3NCVkeHUh?=
NCI-H1963 NXrzcW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHWTWM2OD1zLkCzNlkzKM7:TR?= M2eyfXNCVkeHUh?=
SCC-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSzTWM2OD1zLkCzOFE1KM7:TR?= MV7TRW5ITVJ?
EW-11 M1\QRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILMS5RKSzVyPUGuNFg4PDNizszN M134SXNCVkeHUh?=
CPC-N NYf2VGo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFwMEi4JO69VQ>? NGfkSnVUSU6JRWK=
NCI-H1417 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\3R5lWUUN3ME2xMlEzOjZizszN NVOyPJkzW0GQR1XS
DG-75 M3vk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPvTWM2OD1zLkG2Nlg2KM7:TR?= MmXIV2FPT0WU
HD-MY-Z NUCwXpNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwMU[0NVYh|ryP NYCwTGRHW0GQR1XS
ATN-1 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS5TWM2OD1zLkK2NlA6KM7:TR?= M3nMUHNCVkeHUh?=
KM-H2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XkVWlEPTB;MT6yOlQxQCEQvF2= NH\vVXhUSU6JRWK=
NCI-H2081 M4DITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfNWVlEUUN3ME2xMlI3PjN5IN88US=> MlfKV2FPT0WU
HL-60 M4j3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPmSJVKSzVyPUGuNlY6PTlizszN MYHTRW5ITVJ?
DB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHJfYJwUUN3ME2xMlI4OjR{IN88US=> NVPpSY1VW0GQR1XS
NCI-H1522 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS4fG4xUUN3ME2xMlI5QDh5IN88US=> Mle5V2FPT0WU
AM-38 NY\3UlZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jJNWlEPTB;MT6zNFczKM7:TR?= NYCwSmx2W0GQR1XS
NCI-H446 NF[0dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\EN21KSzVyPUGuN|IyOjFizszN MofOV2FPT0WU
SU-DHL-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rjTWlEPTB;MT6zNlgxOSEQvF2= M1XLOHNCVkeHUh?=
NH-12 NV3NVItbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XOeGlEPTB;MT6zOlM4PCEQvF2= MoLIV2FPT0WU
DMS-79 NFftWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PVUWlEPTB;MT6zOlg3PiEQvF2= M3zHO3NCVkeHUh?=
NCI-H716 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqwXYd2UUN3ME2xMlM5QTh4IN88US=> NInOeVNUSU6JRWK=
ML-2 M2fic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:2SGlEPTB;MT60NVUzQSEQvF2= MVHTRW5ITVJ?
NB10 NWHDZVI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDRcYRyUUN3ME2xMlQ3PjN{IN88US=> NGjXOXFUSU6JRWK=
ONS-76 NGjiZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES2PYtKSzVyPUGuOVM2PjlizszN MnvOV2FPT0WU
LOUCY NI\kUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTac2x1UUN3ME2xMlU1PjV5IN88US=> MXzTRW5ITVJ?
SCLC-21H Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwNUi1PFIh|ryP M{nuWXNCVkeHUh?=
TGW M2q1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS0VpRKSzVyPUGuOlM6PzVizszN M{fheHNCVkeHUh?=
LXF-289 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwN{OyOlgh|ryP M{TER3NCVkeHUh?=
BB49-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwN{O1PFYh|ryP MknsV2FPT0WU
NCI-H747 NX7jbmRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3UeGREUUN3ME2xMlc2OzR4IN88US=> MXXTRW5ITVJ?
LU-165 NVzUbZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwOES5PFYh|ryP M{fnTnNCVkeHUh?=
OMC-1 NEXRSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvQTWM2OD1zLkm1NFY3KM7:TR?= M1Hjc3NCVkeHUh?=
RCC10RGB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwOUW4NVch|ryP NFLkU2hUSU6JRWK=
SW684 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S3cmlEPTB;MT65OlA6QSEQvF2= M4TTeXNCVkeHUh?=
TE-8 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXWXVlKSzVyPUKuNFU2PTlizszN M1Xxd3NCVkeHUh?=
SK-N-DZ NIPtbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSyTWM2OD1{LkGzNlc1KM7:TR?= MUXTRW5ITVJ?
EVSA-T NXWzb3dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKwfIVKSzVyPUKuNVc{OTVizszN NGnFWpFUSU6JRWK=
KASUMI-1 NF\OTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M161b2lEPTB;Mj6xPFgyPSEQvF2= NV\O[5JTW0GQR1XS
NKM-1 M1nsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfQNHhKSzVyPUKuNlU1PzJizszN NH7mWZZUSU6JRWK=
CAL-148 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwM{O2NVQh|ryP NYD5coMyW0GQR1XS
NCI-H64 NHzLWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInzXY5KSzVyPUKuN|QzOzJizszN M3f3ZXNCVkeHUh?=
KNS-81-FD M3;kPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwM{[2NkDPxE1? M3v5eXNCVkeHUh?=
KM12 NE\X[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwNEC4N|kh|ryP NE\qZ|JUSU6JRWK=
SW954 NY\zSJd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPQTWM2OD1{LkS3O|c6KM7:TR?= NF[5N45USU6JRWK=
NCI-H1395 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWxdVlkUUN3ME2yMlUzPjR3IN88US=> MW\TRW5ITVJ?
DJM-1 MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJwNkC2N{DPxE1? MX;TRW5ITVJ?
COLO-668 NUfBVZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TCVGlEPTB;Mj64NlY6PSEQvF2= NEXXO2dUSU6JRWK=
NCI-H1436 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG0TWM2OD1{Lki1OlE2KM7:TR?= MnPSV2FPT0WU
LB2241-RCC NFnkOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C3UWlEPTB;Mj64Olg{QSEQvF2= NHzwS4hUSU6JRWK=
GT3TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwOEmwOVUh|ryP MVTTRW5ITVJ?
COLO-824 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJwOEm3Olgh|ryP NIftd2VUSU6JRWK=
ES1 NH\4PVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjFWXI3UUN3ME2yMlg6QDd7IN88US=> Mn\lV2FPT0WU
LB771-HNC NHPNRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjxV2RFUUN3ME2yMlkxQTR4IN88US=> M{HBT3NCVkeHUh?=
GI-ME-N NVThbFZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLSSINGUUN3ME2zMlAxQTB2IN88US=> M2H0fHNCVkeHUh?=
NALM-6 NGX3e3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:2fGlEPTB;Mz6wNFk{OyEQvF2= NULobnU2W0GQR1XS
LU-134-A Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4noUmlEPTB;Mz6wOVQzPSEQvF2= NEfJWoJUSU6JRWK=
DMS-153 NWfhXIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwMEW4NlQh|ryP MVrTRW5ITVJ?
MZ1-PC M1nhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonXTWM2OD1|LkC5NFc5KM7:TR?= M1Xac3NCVkeHUh?=
NCI-H1155 NULUS242T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm0TWM2OD1|LkGxOlEh|ryP NU\KTJFQW0GQR1XS
CAS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjnSYZKSzVyPUOuNVM4ODdizszN MV7TRW5ITVJ?
D-502MG NUTJcmxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwMUSzPUDPxE1? NIHmW49USU6JRWK=
NCI-H2141 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nZZWlEPTB;Mz6xO|Q2OiEQvF2= MlztV2FPT0WU
NB6 NWSycIdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfL[ZJKSzVyPUOuNVgzPTlizszN NEDWZoRUSU6JRWK=
NCCIT NUDYNHJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\DTWlEPTB;Mz6yNVgxQSEQvF2= NH7FXJBUSU6JRWK=
NB69 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwM{G4PVEh|ryP NHS2XZlUSU6JRWK=
JVM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Lkb2lEPTB;Mz6zOlQ{OyEQvF2= MXHTRW5ITVJ?
K052 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNwM{e5Olgh|ryP MnXhV2FPT0WU
HCC2157 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNwNUOyNlgh|ryP MVTTRW5ITVJ?
KMOE-2 NUP4[GpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwNUSyOFIh|ryP MUHTRW5ITVJ?
SF268 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzFfVJ4UUN3ME2zMlcyPTV2IN88US=> M1;TSXNCVkeHUh?=
CHP-126 NVmxOmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XwZmlEPTB;Mz63OlQ2QCEQvF2= M4LkNHNCVkeHUh?=
CP66-MEL NFn3OFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rNeGlEPTB;Mz63PVA6PCEQvF2= NVP2RW1RW0GQR1XS
NCI-H69 M{TU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XIemlEPTB;ND6wNVk{PiEQvF2= M4j6OXNCVkeHUh?=
A253 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;hOWlEPTB;ND6wNlExOSEQvF2= MWPTRW5ITVJ?
NB14 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvwZmFQUUN3ME20MlExPDd7IN88US=> NVnMXJl7W0GQR1XS
NCI-H1694 M4P0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRwMUOxNVIh|ryP MXPTRW5ITVJ?
NCI-H2196 NELRb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfVWZVTUUN3ME20MlE4OTZ7IN88US=> MmCzV2FPT0WU
TE-9 NWezNFNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Kz[mlEPTB;ND6xO|U5OiEQvF2= M2\Rd3NCVkeHUh?=
D-283MED NVjYdGpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwMUi4OEDPxE1? M4XlRnNCVkeHUh?=
OCI-AML2 NXvRXpBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPuNmhjUUN3ME20MlE6PDh7IN88US=> NH7IbIVUSU6JRWK=
D-263MG M{[3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XnOWlEPTB;ND6yNlk3OSEQvF2= NH;RNGZUSU6JRWK=
MPP-89 NVfPT2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDhPVR6UUN3ME20MlI4OzB2IN88US=> M{DVW3NCVkeHUh?=
LAMA-84 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTvT2xlUUN3ME20MlMxPDJzIN88US=> NUT1T2ZKW0GQR1XS
LB373-MEL-D NEW1bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm2TWM2OD12LkO2O|g6KM7:TR?= M4DuNXNCVkeHUh?=
UACC-257 NE\IS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TBd2lEPTB;ND6zPVU{PCEQvF2= MkXHV2FPT0WU
MC-CAR M{i4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwNEO5PUDPxE1? MUfTRW5ITVJ?
COLO-320-HSR MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TT[GlEPTB;ND60OFQzPyEQvF2= M1TUbnNCVkeHUh?=
P30-OHK NW\Eb4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjsWWpKSzVyPUSuOlY2QDFizszN NEfTUZRUSU6JRWK=
UACC-812 NUTsR|NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HzZmlEPTB;ND62PVE3OSEQvF2= NXq5bYZCW0GQR1XS
CTB-1 NH3iO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInNSZBKSzVyPUSuO|E2PTVizszN M3HjVnNCVkeHUh?=
ALL-PO MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XJSGlEPTB;ND64OFA4PyEQvF2= NXvL[|Z1W0GQR1XS
SK-MEL-2 NXTWWoFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH0VFlRUUN3ME20Mlg3QTV3IN88US=> MXzTRW5ITVJ?
TC-YIK MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTRwOUe5OFIh|ryP NH;KbZJUSU6JRWK=
NCI-H1882 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnDUZlKSzVyPUWuNFIxODFizszN NXiyfYxtW0GQR1XS
MHH-CALL-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXOe5BKSzVyPUWuNFUxPDJizszN MnTJV2FPT0WU
U-87-MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTVwMEm0OlYh|ryP M2W2bXNCVkeHUh?=
NCI-H1092 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjVXIxKSzVyPUWuNlY2PTVizszN M{PlOnNCVkeHUh?=
TE-441-T M3HPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHTTWM2OD13LkK3PFIh|ryP M1\wZnNCVkeHUh?=
SK-MEL-1 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf2bXc6UUN3ME21MlI6ODR2IN88US=> MUHTRW5ITVJ?
EW-22 NFS5NmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rNOGlEPTB;NT6yPVQ3PiEQvF2= MnL1V2FPT0WU
MZ7-mel M2HSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPq[YJKSzVyPUWuOFA3QTFizszN MoDnV2FPT0WU
LP-1 NXv4TYNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne2TWM2OD13LkSxNlkyKM7:TR?= NXe2VXU1W0GQR1XS
NCI-SNU-16 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnuUVNKSzVyPUWuOlQxPzRizszN NFjYU2JUSU6JRWK=
LU-65 M2LLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LheGlEPTB;NT63OlM4OyEQvF2= MlTOV2FPT0WU
CW-2 NUfzU5dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWriWGw2UUN3ME21Mlg2QTV7IN88US=> M3PpOnNCVkeHUh?=
WSU-NHL MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\mZZVKSzVyPUWuPVUyPzRizszN NVfHXoVSW0GQR1XS
IST-MES1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPsTWM2OD13Lkm1OFQ{KM7:TR?= M{TwSHNCVkeHUh?=
U-266 M4XUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDLb|JKSzVyPUWuPVgzODJizszN NXuyWplYW0GQR1XS
TALL-1 NE\RVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXmVGpjUUN3ME22MlE1Pjh6IN88US=> MknYV2FPT0WU
Calu-6 NV3CTIZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfxTWM2OD14LkG1N|E3KM7:TR?= NGLNWWRUSU6JRWK=
MMAC-SF NVX1SlB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O1dWlEPTB;Nj6xPFU2PiEQvF2= NYnmbGpbW0GQR1XS
NCI-H82 M4TM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjBUVMxUUN3ME22MlIxPDh7IN88US=> NHrySlBUSU6JRWK=
RS4-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTZwMkW4PVch|ryP NXfWVnpCW0GQR1XS
SNU-C2B M3XHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfFV4xKSzVyPU[uOFA6PjlizszN M2P5VHNCVkeHUh?=
BOKU MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LHWmlEPTB;Nj60O|U6PyEQvF2= NY\vR2xMW0GQR1XS
C8166 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TnXGlEPTB;Nj61OVkyOiEQvF2= M2P5eHNCVkeHUh?=
D-247MG MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO1UmhKSzVyPUeuNFQ{PDdizszN Mn\CV2FPT0WU
EW-18 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzUTWM2OD15LkC3NlkzKM7:TR?= M33jbnNCVkeHUh?=
KG-1 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LUV2lEPTB;Nz62Nlc{QCEQvF2= MmXaV2FPT0WU
REH MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XaemlEPTB;Nz62PFExQSEQvF2= M1zlVXNCVkeHUh?=
U-698-M MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\hTWM2OD15Lki0N|E2KM7:TR?= NFzqb4JUSU6JRWK=
KP-N-RT-BM-1 NEX4R5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvETWM2OD15LkmzNFI6KM7:TR?= NX7QXldJW0GQR1XS
MS-1 NELEeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfqW3pKSzVyPUeuPVYxPDFizszN MXjTRW5ITVJ?
SNU-C1 NF3hXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjHWZBKSzVyPUeuPVgyQTJizszN M2C4PHNCVkeHUh?=
SK-MM-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTLUHB4UUN3ME24MlI3ODZ3IN88US=> NYPabHh1W0GQR1XS
LAN-6 M3\2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm0Z3JKSzVyPUiuN|AxODFizszN NUC5ZpBWW0GQR1XS
NEC8 NWm0UWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XWR2lEPTB;OD6zNFY6OSEQvF2= MkjFV2FPT0WU
NCI-H1770 M3\sWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37pdGlEPTB;OD6zPFAxOiEQvF2= MlnqV2FPT0WU
D-336MG MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRThwNECxNVYh|ryP Ml\0V2FPT0WU
COLO-829 MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEThNZRKSzVyPUiuOFg5PzlizszN NV\OSoZHW0GQR1XS
LS-513 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXiTWM2OD16LkW5OVk6KM7:TR?= MoPFV2FPT0WU
YT MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRThwNkK0Nlch|ryP NEGzb3RUSU6JRWK=
EW-24 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThwN{[1OEDPxE1? MoXyV2FPT0WU
IST-SL1 NHLTOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRThwOE[1OFMh|ryP MUnTRW5ITVJ?
CA46 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThwOUWwPVgh|ryP MYfTRW5ITVJ?
NCI-H1838 M3XROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33NNWlEPTB;OD65PFYxOiEQvF2= MonkV2FPT0WU
NCI-H719 NW\Yd205T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK5bmxmUUN3ME25MlI2Ojd7IN88US=> NY\QZWJoW0GQR1XS
HCE-T M1[0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jSXmlEPTB;OT6zNFg2OSEQvF2= MnXBV2FPT0WU
A498 M4\ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PFSmlEPTB;OT6zOlEzPCEQvF2= NHnLboNUSU6JRWK=
LB831-BLC NXrpNW1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6zV4lrUUN3ME25Mlc3PTJzIN88US=> NV7uVndkW0GQR1XS
SKM-1 MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHwSZZLUUN3ME25Mlg2QTZ|IN88US=> MXnTRW5ITVJ?
THP-1 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7OT3VKSzVyPUmuPVY6OThizszN NUnmOnFOW0GQR1XS
SHP-77 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PE[GlEPTB;MUCuOFA4KM7:TR?= M{X6dnNCVkeHUh?=
EW-3 NE\0N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf5[2JKSzVyPUGwMlYzQDlizszN NILLUpRUSU6JRWK=
KY821 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ntNWlEPTB;MUCuO|Y{KM7:TR?= MnzBV2FPT0WU
NCI-SNU-1 M{XzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHSTWM2OD1zMT6wNlE4KM7:TR?= M2\KO3NCVkeHUh?=
HCC2218 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf5PWxKSzVyPUGxMlM6QDZizszN MX\TRW5ITVJ?
IM-9 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFzLkWxNFYh|ryP M{fLSXNCVkeHUh?=
NCI-H889 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke3TWM2OD1zMT61N|E{KM7:TR?= NV;YVVdrW0GQR1XS
HDLM-2 NWHmW4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjzTWM2OD1zMj60NVU6KM7:TR?= MWTTRW5ITVJ?
LB2518-MEL MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF{Lk[4NVUh|ryP MXrTRW5ITVJ?
NCI-H23 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17LO2lEPTB;MUOuNlQzPSEQvF2= NYXYeoVDW0GQR1XS
NB17 M4rkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTTOlVKSzVyPUGzMlQ2PzlizszN MYPTRW5ITVJ?
NCI-H322M MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnJNm5KSzVyPUG0MlQxPjhizszN M3TNfXNCVkeHUh?=
SUP-T1 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHDWllKSzVyPUG0MlQyOyEQvF2= NGLzTIRUSU6JRWK=
ES3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXiTWM2OD1zNT6wO|A{KM7:TR?= MnTtV2FPT0WU
ES5 Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXlc4R1UUN3ME2xOU4xPzh5IN88US=> MnzDV2FPT0WU
NCI-H1650 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGThWGVKSzVyPUG1MlQ6PzlizszN NGL3fo1USU6JRWK=
NCI-H226 M{LkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzOTWM2OD1zNT64O|Y5KM7:TR?= M4j1dXNCVkeHUh?=
COR-L88 M4DNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPOTWM2OD1zNj6zNVQh|ryP M{\aTHNCVkeHUh?=
SCC-15 M2X5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvqepdbUUN3ME2xOk4{QDZ7IN88US=> NUTDd4J{W0GQR1XS
GOTO NIrLXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P3V2lEPTB;MU[uOFc6OyEQvF2= NIj0RXVUSU6JRWK=
SIMA MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF4LkS4NFIh|ryP MmnzV2FPT0WU
NCI-H1299 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TOW2lEPTB;MUeuNVU6OSEQvF2= NFG4SYVUSU6JRWK=
NCI-H1581 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7NTJlKSzVyPUG3MlQzOTlizszN NXXs[ZlrW0GQR1XS
MHH-NB-11 NYrIeGV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHUVlVKSzVyPUG3Mlk3QDNizszN NHj2[HdUSU6JRWK=
MFM-223 NF\qVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXqeoMzUUN3ME2xPE4xPTN6IN88US=> Mn;OV2FPT0WU
ES7 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF6LkW0N|Eh|ryP MV\TRW5ITVJ?
JVM-3 M1y3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3TTWM2OD1zOD63NVch|ryP M2\uTHNCVkeHUh?=
RL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJyLkO4PEDPxE1? M{fM[3NCVkeHUh?=
EC-GI-10 NUnQTXRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7LUYxKSzVyPUKxMlIxPDFizszN MojzV2FPT0WU
LNCaP-Clone-FGC NGTTVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJzLk[3Olgh|ryP MXrTRW5ITVJ?
IMR-5 M1ja[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X2N2lEPTB;MkGuPFQ6PCEQvF2= NHHLVnBUSU6JRWK=
KP-N-YS NI\IfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofJTWM2OD1{MT64O|Uh|ryP NFLw[4ZUSU6JRWK=
Mo-T NFTzN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ{LkKxPFUh|ryP M3i2TnNCVkeHUh?=
NCI-H128 M3;uVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX64VnNSUUN3ME2yN{42QDV|IN88US=> MYrTRW5ITVJ?
RH-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmiwTWM2OD1{Mz63PFY3KM7:TR?= M1\SbnNCVkeHUh?=
NCI-H2171 M{f0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\CUWlEPTB;MkSuNlQ5PSEQvF2= M2rlWXNCVkeHUh?=
RPMI-8866 M3LuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz1bpY6UUN3ME2yOk44PDJizszN MXjTRW5ITVJ?
SK-N-FI MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETDPHRKSzVyPUK3MlM5OTFizszN NHnMT|lUSU6JRWK=
LOXIMVI M3vjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\mTWM2OD1{Nz64NFUyKM7:TR?= M13GeHNCVkeHUh?=
P31-FUJ MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT2UpFKSzVyPUOxMlU{PzRizszN M2foUHNCVkeHUh?=
KMS-12-PE MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR7LkWzNFIh|ryP NVnoNopzW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID